Vascular Therapies Completes Enrollment in Phase III ACCESS 2 Study for Sirogen

Vascular Therapies has announced the completion of enrollment in the ACCESS 2 trial, a Phase III multinational randomized clinical study evaluating Sirogen. This study aims to improve outcomes for arteriovenous (AV) fistula creation in hemodialysis patients.

Sirogen, a proprietary sirolimus formulation, has shown promise in improving fistula maturation and secondary patency compared to standard care in previous studies. ACCESS 2 seeks to validate these findings with 12_ patients across 18 centers in the U.S. and U.K. Topline results, including clinical fistula maturation at six months, are expected in Q2 2025.

Vascular Therapies CEO, John McDermott, expressed confidence in Sirogen’s potential to reduce failure rates and reinterventions, thus lowering patient morbidity and healthcare costs. Chief Scientific Officer, Sriram Iyer, emphasized the importance of this study in addressing unmet clinical needs.